Back to search results

Travoprost Implant and iStent Infinite for Glaucoma

This study is testing two treatments for open-angle glaucoma or ocular hypertension (high pressure in the eye): a Travoprost Intraocular Implant and the iStent infinite device. You might be eligible if you have one of these conditions and a specific eye pressure. The study aims to see how much these treatments can lower your eye pressure after 3 months. We don't know the current recruitment status, but the study plans to enroll 150 people.

Study design
This is an interventional study where participants are randomly assigned to receive either the iStent infinite plus the Travoprost Intraocular Implant, or a sham procedure (a fake procedure to mimic the iStent placement) plus the Travoprost Intraocular Implant. The study plans to enroll 150 people.
What's involved
Adult subjects will receive either the iStent infinite trabecular bypass system plus a travoprost intraocular implant or a sham procedure plus a travoprost intraocular implant. You will be followed for 12 months.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed for 12 months after receiving treatment.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06066645

Travoprost Intraocular Implant + iStent Infinite

Recruiting
PHASE4Ages 18+InterventionalTreatment
Glaukos Corporation
~150 participants
Updated 2026-06-02 on ClinicalTrials.gov
What's tested:Travoprost Intraocular ImplantiStent infiniteSham procedure

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
change from baseline in mean diurnal intraocular pressure (IOP)
Measured over 3 months

Conditions

Glaucoma, Open-Angle

Explore related trials

Ocular HypertensionOpen Angle Glaucoma

Where it's being run

1 sites across 1 states
Oklahoma1

Study leadership

  • Study Director · STUDY_DIRECTOR · Glaukos Corporation

Who to contact

Study Director
[email protected]
949-739-8749
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

diagnosis of open-angle glaucoma or ocular hypertension
qualifying IOP in the study eye

Exclusion

unmedicated (washed out) IOP of \>36 mmHg in the study eye
hypersensitivity to travoprost or any other components of the travoprost intraocular implant
vertical cup/disc ratio \> 0.8 in the study eye
best spectacle corrected visual acuity of worse than 20/80 in either eye
any ocular disease or condition that, in the opinion of the investigator, may put the subject at significant risk, may confound the study results, or may interfere significantly with the subject's participation in the study

What this trial measures

  • change from baseline in mean diurnal intraocular pressure (IOP)3 months

    mean diurnal IOP at the 3 month visit minus mean diurnal IOP at baseline